Structurally enabled discovery of adenosine a2a receptor antagonists

Chemical Reviews

Volumn 117, Issue 1, 2017, Pages 21-37

  Jazayeri, Ali ^a   Andrews, Stephen P ^a,b   Marshall, Fiona H ^a  

^a Heptares Therapeutics Ltd   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINS;

CLINICAL DEVELOPMENT; G-PROTEIN COUPLED RECEPTORS; HIGH-RESOLUTION STRUCTURES; INNOVATIVE RESEARCH; PHARMACEUTICAL INDUSTRY; RECEPTOR ANTAGONISTS; STRUCTURAL INFORMATION; STRUCTURE BASED DRUG DESIGNS;

DRUG INTERACTIONS;

ADENOSINE A2A RECEPTOR;

ANIMAL; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; HUMAN; INFLAMMATION; METABOLISM; MOUSE; NEOPLASM; PROTEIN CONFORMATION; RESPIRATORY TRACT DISEASE; X RAY CRYSTALLOGRAPHY;

ANIMALS; CRYSTALLOGRAPHY, X-RAY; DRUG DISCOVERY; HUMANS; INFLAMMATION; MICE; NEOPLASMS; PROTEIN CONFORMATION; RECEPTOR, ADENOSINE A2A; RESPIRATORY TRACT DISEASES;

EID: 85020139339     PISSN: 00092665     EISSN: 15206890     Source Type: Journal    
DOI: 10.1021/acs.chemrev.6b00119     Document Type: Review

References (153)

1. Congreve, M.; Dias, J. M.; Marshall, F. H. Structure-Based Drug Design for G Protein-Coupled Receptors. Prog. Med. Chem. 2014, 53, 1-63.
2. Komatsu, H. Novel Therapeutic GPCRs for Psychiatric Disorders. Int. J. Mol. Sci. 2015, 16 (6), 14109-14121.
3. Capote, L. A.; Mendez Perez, R.; Lymperopoulos, A. GPCR Signaling and Cardiac Function. Eur. J. Pharmacol. 2015, 763, 143-148.
4. Penn, R.; Bond, R.; Walker, J. GPCRs and Arrestins in Airways: Implications for Asthma. Handb. Exp. Pharmacol. 2014, 219, 387-403.
5. Zhu, L.; Zhao, Q.; Wu, B. Structure-Based Studies of Chemokine Receptors. Curr. Opin. Struct. Biol. 2013, 23 (4), 539-546.
6. Sanger, G. J.; Furness, J. B. Ghrelin and Motilin Receptors as Drug Targets for Gastrointestinal Disorders. Nat. Rev. Gastroenterol. Hepatol. 2016, 13 (1), 38-48.
7. O'Hayre, M.; Degese, M. S.; Gutkind, J. S. Novel Insights into G Protein and G Protein-Coupled Receptor Signaling in Cancer. Curr. Opin. Cell Biol. 2014, 27 (1), 126-135.
8. Thompson, M. D.; Hendy, G. N.; Percy, M. E.; Bichet, D. G.; Cole, D. E. G Protein-Coupled Receptor Mutations and Human Genetic Disease. Methods Mol. Biol. 2014, 1175, 153-187.
9. Lee-Iannotti, J. K.; Parish, J. M. Suvorexant: A Promising, Novel Treatment for Insomnia. Neuropsychiatr. Dis. Treat. 2016, 491-495.
10. Cunningham, M.; McIntosh, K.; Bushell, T.; Sloan, G.; Plevin, R. Proteinase-Activated Receptors (PARs) as Targets for Antiplatelet Therapy. Biochem. Soc. Trans. 2016, 44 (2), 606-612.
11. Vij, M.; Drake, M. J. Clinical Use of the 3 Adrenoceptor Agonist Mirabegron in Patients with Overactive Bladder Syndrome. Ther. Adv. Urol. 2015, 7 (5), 241-248.
12. Shand, J.; Menown, I.; Storey, R. Ticagrelor: From Concept to Clinical Evaluation. Biomarkers Med. 2011, 5 (1), 53-62.
13. Wilhelm, S.; Lipari, M.; Kulik, J.; Kale-Pradhan, P. Teduglutide for the Treatment of Short Bowel Syndrome. Ann. Pharmacother. 2014, 48 (9), 1209-1213.
14. Nix, N. M.; Burdine, O.; Walker, M. Vismodegib: First-in-Class Hedgehog Pathway Inhibitor for Metastatic or Locally Advanced Basal Cell Carcinoma. J. Adv. Pract. Oncol. 2014, 5 (4), 294-296.
15. Shukla, A. P.; Kumar, R. B.; Aronne, L. J. Lorcaserin Hcl for the Treatment of Obesity. Expert Opin. Pharmacother. 2015, 16 (16), 2531-2538.
16. Khatri, B. Fingolimod in the Treatment of Relapsing-remitting Multiple Sclerosis: Long-Term Experience and an Update on the Clinical Evidence. Ther. Adv. Neurol. Disord. 2016, 9 (2), 130-147.
17. Spooner, L.; Olin, J. esamorelin: A Growth Hormone-Releasing Factor Analogue for HIV-Associated Lipodystrophy. Ann. Pharmacother. 2012, 46 (2), 240-247.
18. Cooke, R. M.; Brown, A. J. H.; Marshall, F. H.; Mason, J. S. Structures of G Protein-Coupled Receptors Reveal New Opportunities for Drug Discovery. Drug Discovery Today 2015, 20 (11), 1355-1364.
19. Preti, D.; Baraldi, P. G.; Moorman, A. R.; Borea, P. A.; Varani, K. History and Perspectives of A2A Adenosine Receptor Antagonists as Potential Therapeutic Agents. Med. Res. Rev. 2015, 35 (4), 790-848.
20. Cunha, R. A.; Ferre, S.; Vaugeois, J. M.; Chen, J. F. Potential Therapeutic Interest of Adenosine A2A Receptors in Psychiatric Disorders. Curr. Pharm. Des. 2008, 14 (15), 1512-1524.
21. Jenner, P. An Overview of Adenosine A2A Receptor Antagonists in Parkinson's Disease. Int. Rev. Neurobiol. 2014, 119, 71-86.
22. Vorovenci, R. J.; Antonini, A. The Efficacy of Oral Adenosine A(2A) Antagonist Istradefylline for the Treatment of Moderate to Severe Parkinson's Disease. Expert Rev. Neurother. 2015, 15 (12), 1383-1390.
23. Pires, V. A.; Pamplona, F. A.; Pandolfo, P.; Fernandes, D.; Prediger, R. D.; Takahashi, R. N. Adenosine Receptor Antagonists Improve Short-Term Object-Recognition Ability of Spontaneously Hypertensive Rats: A Rodent Model of Attention-Deficit Hyperactivity Disorder. Behav. Pharmacol. 2009, 20 (2), 134-145.
24. Leone, R. D.; Lo, Y.-C.; Powell, J. D. A2aR Antagonists: Next Generation Checkpoint Blockade for Cancer Immunotherapy. Comput. Struct. Biotechnol. J. 2015, 13, 265-272.
25. Sitkovsky, M. V.; Hatfield, S.; Abbott, R.; Belikoff, B.; Lukashev, D.; Ohta, A. Hostile, Hypoxia-A2-Adenosinergic Tumor Biology as the next Barrier to Overcome for Tumor Immunologists. Cancer Immunol. Res. 2014, 2 (7), 598-605.
26. Congreve, M.; Langmead, C. J.; Mason, J. S.; Marshall, F. H. Progress in Structure Based Drug Design for G Protein-Coupled Receptors. J. Med. Chem. 2011, 54 (13), 4283-4311.
27. Leeson, P. D.; Springthorpe, B. The Influence of Drug-like Concepts on Decision-Making in Medicinal Chemistry. Nat. Rev. Drug Discovery 2007, 6 (11), 881-890.
28. Rimkus, T.; Carpenter, R.; Qasem, S.; Chan, M.; Lo, H.-W. Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors. Cancers 2016, 8 (2), No. 22.
29. Gonzalez-Cabrera, P. J.; Brown, S.; Studer, S. M.; Rosen, H. S1P Signaling: New Therapies and Opportunities. F1000Prime Rep. 2014, 6, No. 109.
30. Prasad-Reddy, L.; Isaacs, D. A Clinical Review of GLP-1 Receptor Agonists: Efficacy and Safety in Diabetes and Beyond. Drugs Context 2015, 4, No. 212283.
31. Siller-Matula, J. M.; Jilma, B. Ticagrelor: From Discovery to Phase III Clinical Trial. Future Cardiol. 2010, 6 (6), 753-764.
32. Manglik, A.; Kim, T. H.; Masureel, M.; Altenbach, C.; Yang, Z.; Hilger, D.; Lerch, M. T.; Kobilka, T. S.; Thian, F. S.; Hubbell, W. L.; et al. Structural Insights into the Dynamic Process of β2-Adrenergic Receptor Signaling. Cell 2015, 162 (6), 1431.
33. Robertson, N.; Jazayeri, A.; Errey, J.; Baig, A.; Hurrell, E.; Zhukov, A.; Langmead, C. J.; Weir, M.; Marshall, F. H. The Properties of Thermostabilised G Protein-Coupled Receptors (StaRs) and Their Use in Drug Discovery. Neuropharmacology 2011, 60 (1), 36-44.
34. Magnani, F.; Shibata, Y.; Serrano-Vega, M. J.; Tate, C. G. Co-Evolving Stability and Conformational Homogeneity of the Human Adenosine A2a Receptor. Proc. Natl. Acad. Sci. U. S. A. 2008, 105 (31), 10744-10749.
35. Lebon, G.; Bennett, K.; Jazayeri, A.; Tate, C. G. Thermostabilisation of an Agonist-Bound Conformation of the Human Adenosine A(2A) Receptor. J. Mol. Biol. 2011, 409 (3), 298-310.
36. Shibata, Y.; White, J. F.; Serrano-Vega, M. J.; Magnani, F.; Aloia, A. L.; Grisshammer, R.; Tate, C. G. Thermostabilization of the Neurotensin Receptor NTS1. J. Mol. Biol. 2009, 390 (2), 262-277.
37. Serrano-Vega, M. J.; Magnani, F.; Shibata, Y.; Tate, C. G. Conformational Thermostabilization of the beta1-Adrenergic Receptor in a Detergent-Resistant Form. Proc. Natl. Acad. Sci. U. S. A. 2008, 105 (3), 877-882.
38. Miller, J. L.; Tate, C. G. Engineering an Ultra-Thermostable β(1)-Adrenoceptor. J. Mol. Biol. 2011, 413 (3), 628-638.
39. Tan, Q.; Zhu, Y.; Li, J.; Chen, Z.; Han, G. W.; Kufareva, I.; Li, T.; Ma, L.; Fenalti, G.; Li, J.; et al. Structure of the CCR5 Chemokine Receptor-HIV Entry Inhibitor Maraviroc Complex. Science 2013, 341 (6152), 1387-1390.
40. Srivastava, A.; Yano, J.; Hirozane, Y.; Kefala, G.; Gruswitz, F.; Snell, G.; Lane, W.; Ivetac, A.; Aertgeerts, K.; Nguyen, J.; et al. High-Resolution Structure of the Human GPR40 Receptor Bound to Allosteric Agonist TAK-875. Nature 2014, 513 (7516), 124-127.
41. Doré, A. S.; Okrasa, K.; Patel, J. C.; Serrano-Vega, M.; Bennett, K.; Cooke, R. M.; Errey, J. C.; Jazayeri, A.; Khan, S.; Tehan, B.; et al. Structure of Class C GPCR Metabotropic Glutamate Receptor 5 Transmembrane Domain. Nature 2014, 511 (7511), 557-562.
42. Hollenstein, K.; Kean, J.; Bortolato, A.; Cheng, R. K. Y.; Doré, A. S.; Jazayeri, A.; Cooke, R. M.; Weir, M.; Marshall, F. H. Structure of Class B GPCR Corticotropin-Releasing Factor Receptor 1. Nature 2013, 499 (7459), 438-443.
43. Kean, J.; Bortolato, A.; Hollenstein, K.; Marshall, F. H.; Jazayeri, A. Conformational Thermostabilisation of Corticotropin Releasing Factor Receptor 1. Sci. Rep. 2015, 5, No. 11954.
44. Doré, A. S.; Robertson, N.; Errey, J. C.; Ng, I.; Hollenstein, K.; Tehan, B.; Hurrell, E.; Bennett, K.; Congreve, M.; Magnani, F.; et al. Structure of the Adenosine A(2A) Receptor in Complex with ZM241385 and the Xanthines XAC and Caffeine. Structure 2011, 19 (9), 1283-1293.
45. Sarkar, C. a; Dodevski, I.; Kenig, M.; Dudli, S.; Mohr, A.; Hermans, E.; Plückthun, A. Directed Evolution of a G Protein-Coupled Receptor for Expression, Stability, and Binding Selectivity. Proc. Natl. Acad. Sci. U. S. A. 2008, 105 (39), 14808-14813.
46. Dodevski, I.; Plückthun, A. Evolution of Three Human GPCRs for Higher Expression and Stability. J. Mol. Biol. 2011, 408 (4), 599-615.
47. Scott, D. J.; Kummer, L.; Egloff, P.; Bathgate, R. A. D.; Plückthun, A. Improving the Apo-State Detergent Stability of NTS1 with CHESS for Pharmacological and Structural Studies. Biochim. Biophys. Acta, Biomembr. 2014, 1838 (11), 2817-2824.
48. Scott, D. J.; Plückthun, A. Direct Molecular Evolution of Detergent-Stable G Protein-Coupled Receptors Using Polymer Encapsulated Cells. J. Mol. Biol. 2013, 425 (3), 662-677.
49. Schütz, M.; Schöppe, J.; Sedlák, E.; Hillenbrand, M.; Nagy-Davidescu, G.; Ehrenmann, J.; Klenk, C.; Egloff, P.; Kummer, L.; Plückthun, A. Directed Evolution of G Protein-Coupled Receptors in Yeast for Higher Functional Production in Eukaryotic Expression Hosts. Sci. Rep. 2016, 6 (1), 21508.
50. Chen, Q.; Miller, L. J.; Dong, M. Role of N-Linked Glycosylation in Biosynthesis, Trafficking, and Function of the Human Glucagon-like Peptide 1 Receptor. Am. J. Physiol.-Endocrinol. Metab. 2010, 299 (1), E62-E68.
51. Bennett, K. a; Tehan, B.; Lebon, G.; Tate, C. G.; Weir, M.; Marshall, F. H.; Langmead, C. J. Pharmacology and Structure of Isolated Conformations of the Adenosine A2A Receptor Define Ligand Efficacy. Mol. Pharmacol. 2013, 83 (5), 949-958.
52. Siu, F. Y.; He, M.; de Graaf, C.; Han, G. W.; Yang, D.; Zhang, Z.; Zhou, C.; Xu, Q.; Wacker, D.; Joseph, J. S.; et al. Structure of the Human Glucagon Class B G-Protein-Coupled Receptor. Nature 2013, 499 (7459), 444-449.
53. Jazayeri, A.; Doré, A. S.; Lamb, D.; Krishnamurthy, H.; Southall, S. M.; Baig, A. H.; Bortolato, A.; Koglin, M.; Robertson, N. J.; Errey, J. C.; et al. Extra-Helical Binding Site of a Glucagon Receptor Antagonist. Nature 2016, 533 (7602), 274-277.
54. Penmatsa, A.; Wang, K. H.; Gouaux, E. X-Ray Structures of Drosophila Dopamine Transporter in Complex with Nisoxetine and Reboxetine. Nat. Struct. Mol. Biol. 2015, 22, 506-508.
55. Penmatsa, A.; Wang, K. H.; Gouaux, E. X-Ray Structure of Dopamine Transporter Elucidates Antidepressant Mechanism. Nature 2013, 503 (7474), 85-90.
56. Wang, K. H.; Penmatsa, A.; Gouaux, E. Neurotransmitter and Psychostimulant Recognition by the Dopamine Transporter. Nature 2015, 521 (May), 322-327.
57. Green, E. M.; Coleman, J. A.; Gouaux, E. Thermostabilization of the Human Serotonin Transporter in an Antidepressant-Bound Conformation. PLoS One 2015, 10 (12), No. e0145688.
58. Chen, L.; Durr, K. L.; Gouaux, E. Activation Mechanism of AMPA Receptors Illuminated by Complexes with Cone Snail Toxin, Allosteric Potentiator and Orthosteric Agonists. Science 2014, 345 (6200), 1021-1026.
59. Lee, C.-H.; Lü, W.; Michel, J. C.; Goehring, A.; Du, J.; Song, X.; Gouaux, E. NMDA Receptor Structures Reveal Subunit Arrangement and Pore Architecture. Nature 2014, 511 (7508), 191-197.
60. Abdul-Hussein, S.; Andréll, J.; Tate, C. G. Thermostabilisation of the Serotonin Transporter in a Cocaine-Bound Conformation. J. Mol. Biol. 2013, 425 (12), 2198-2207.
61. Rasmussen, S. G. F.; Choi, H.-J.; Rosenbaum, D. M.; Kobilka, T. S.; Thian, F. S.; Edwards, P. C.; Burghammer, M.; Ratnala, V. R. P.; Sanishvili, R.; Fischetti, R. F.; et al. Crystal Structure of the Human beta2 Adrenergic G-Protein-Coupled Receptor. Nature 2007, 450 (7168), 383-387.
62. Rosenbaum, D. M.; Cherezov, V.; Hanson, M. a; Rasmussen, S. G. F.; Thian, F. S.; Kobilka, T. S.; Choi, H.-J.; Yao, X.-J.; Weis, W. I.; Stevens, R. C.; et al. GPCR Engineering Yields High-Resolution Structural Insights into beta2-Adrenergic Receptor Function. Science 2007, 318 (5854), 1266-1273.
63. Chun, E.; Thompson, A. a.; Liu, W.; Roth, C. B.; Griffith, M. T.; Katritch, V.; Kunken, J.; Xu, F.; Cherezov, V.; Hanson, M. a.; et al. Fusion Partner Toolchest for the Stabilization and Crystallization of G Protein-Coupled Receptors. Structure 2012, 20 (6), 967-976.
64. Yin, J.; Mobarec, J. C.; Kolb, P.; Rosenbaum, D. M. Crystal Structure of the Human OX2 Orexin Receptor Bound to the Insomnia Drug Suvorexant. Nature 2014, 519 (7542), 247-250.
65. Rasmussen, S. G. F.; Choi, H.-J.; Fung, J. J.; Pardon, E.; Casarosa, P.; Chae, P. S.; DeVree, B. T.; Rosenbaum, D. M.; Thian, F. S.; Kobilka, T. S.; et al. Structure of a Nanobody-Stabilized Active State of the β(2) Adrenoceptor. Nature 2011, 469 (7329), 175-180.
66. Steyaert, J.; Kobilka, B. K. Nanobody Stabilization of G Protein-Coupled Receptor Conformational States. Curr. Opin. Struct. Biol. 2011, 21 (4), 567-572.
67. Ring, A. M.; Manglik, A.; Kruse, A. C.; Enos, M. D.; Weis, W. I.; Garcia, K. C.; Kobilka, B. K. Adrenaline-Activated Structure of β2-Adrenoceptor Stabilized by an Engineered Nanobody. Nature 2013, 502, 575-579.
68. Manglik, A.; Kruse, A. C.; Kobilka, T. S.; Thian, F. S.; Mathiesen, J. M.; Sunahara, R. K.; Pardo, L.; Weis, W. I.; Kobilka, B. K.; Granier, S. Crystal Structure of the μ-Opioid Receptor Bound to a Morphinan Antagonist. Nature 2012, 485 (7398), 321-326.
69. Kruse, A. C.; Ring, A. M.; Manglik, A.; Hu, J.; Hu, K.; Eitel, K.; Hübner, H.; Pardon, E.; Valant, C.; Sexton, P. M.; et al. Activation and Allosteric Modulation of a Muscarinic Acetylcholine Receptor. Nature 2013, 504 (7478), 101-106.
70. Chae, P. S.; Kruse, A. C.; Gotfryd, K.; Rana, R. R.; Cho, K. H.; Rasmussen, S. G. F.; Bae, H. E.; Chandra, R.; Gether, U.; Guan, L.; et al. New Tripod Amphiphiles for Membrane Protein Analysis. Chem.-Eur. J. 2013, 19 (46), 15645-15651.
71. Tao, H.; Fu, Y.; Thompson, A.; Lee, S. C.; Mahoney, N.; Stevens, R. C.; Zhang, Q. Synthesis and Properties of Dodecyl Trehaloside Detergents for Membrane Protein Studies. Langmuir 2012, 28 (30), 11173-11181.
72. Lee, S. C.; Bennett, B. C.; Hong, W.-X.; Fu, Y.; Baker, K. a; Marcoux, J.; Robinson, C. V.; Ward, A. B.; Halpert, J. R.; Stevens, R. C.; et al. Steroid-Based Facial Amphiphiles for Stabilization and Crystallization of Membrane Proteins. Proc. Natl. Acad. Sci. U. S. A. 2013, 110 (13), E1203-E1211.
73. Chae, P. S.; Rasmussen, S. G. F.; Rana, R. R.; Gotfryd, K.; Chandra, R.; Goren, M. a; Kruse, A. C.; Nurva, S.; Loland, C. J.; Pierre, Y.; et al. Maltose-Neopentyl Glycol (MNG) Amphiphiles for Solubilization, Stabilization and Crystallization of Membrane Proteins. Nat. Methods 2010, 7 (12), 1003-1008.
74. Caffrey, M. A Comprehensive Review of the Lipid Cubic Phase or in Meso Method for Crystallizing Membrane and Soluble Proteins and Complexes. Acta Crystallogr., Sect. F: Struct. Biol. Commun. 2015, 71, 3-18.
75. Cherezov, V. Lipidic Cubic Phase Technologies for Membrane Protein Structural Studies. Curr. Opin. Struct. Biol. 2011, 21 (4), 559-566.
76. Weierstall, U.; James, D.; Wang, C.; White, T. a; Wang, D.; Liu, W.; Spence, J. C. H.; Bruce Doak, R.; Nelson, G.; Fromme, P.; et al. Lipidic Cubic Phase Injector Facilitates Membrane Protein Serial Femtosecond Crystallography. Nat. Commun. 2014, 5, No. 3309.
77. Liu, W.; Wacker, D.; Gati, C.; Han, G. W.; James, D.; Wang, D.; Nelson, G.; Weierstall, U.; Katritch, V.; Barty, A.; et al. Serial Femtosecond Crystallography of G Protein-Coupled Receptors. Science 2013, 342 (6165), 1521-1524.
78. Liu, W.; Ishchenko, A.; Cherezov, V. Preparation of Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography. Nat. Protoc. 2014, 9 (9), 2123-2134.
79. Zhang, H.; Unal, H.; Gati, C.; Han, G. W.; Liu, W.; Zatsepin, N. A.; James, D.; Wang, D.; Nelson, G.; Weierstall, U.; et al. Structure of the Angiotensin Receptor Revealed by Serial Femtosecond Crystallography. Cell 2015, 161, 833-844.
80. Jaakola, V.-P.; Griffith, M. T.; Hanson, M. a; Cherezov, V.; Chien, E. Y. T.; Lane, J. R.; Ijzerman, A. P.; Stevens, R. C. The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist. Science 2008, 322 (5905), 1211-1217.
81. Xu, F.; Wu, H.; Katritch, V.; Han, G. W.; Jacobson, K. A.; Gao, Z.-G.; Cherezov, V.; Stevens, R. C. Structure of an Agonist-Bound Human A2A Adenosine Receptor. Science 2011, 332 (6027), 322-327.
82. Lebon, G.; Warne, T.; Edwards, P. C.; Bennett, K.; Langmead, C. J.; Leslie, A. G. W.; Tate, C. G. Agonist-Bound Adenosine A2A Receptor Structures Reveal Common Features of GPCR Activation. Nature 2011, 474 (7352), 521-525.
83. Hino, T.; Arakawa, T.; Iwanari, H.; Yurugi-Kobayashi, T.; Ikeda-Suno, C.; Nakada-Nakura, Y.; Kusano-Arai, O.; Weyand, S.; Shimamura, T.; Nomura, N.; et al. G Protein-Coupled Receptor Inactivation by an Allosteric Inverse-Agonist Antibody. Nature 2012, 482 (7384), 237-240.
84. Congreve, M.; Andrews, S. P.; Dore, A. S.; Hollenstein, K.; Hurrell, E.; Langmead, C. J.; Mason, J. S.; Ng, I. W.; Tehan, B.; Zhukov, A.; et al. Discovery of 1, 2, 4-Triazine Derivatives as Adenosine A(2A) Antagonists Using Structure Based Drug Design. J. Med. Chem. 2012, 55 (5), 1898-1903.
85. Liu, W.; Chun, E.; Thompson, A. A.; Chubukov, P.; Xu, F.; Han, G. W.; Roth, C. B.; Heitman, L. H.; Ijzerman, A. P.; Cherezov, V.; et al. Structural Basis for Allosteric Regulation of GPCRs by Sodium Ions. Science 2012, 337 (6091), 232-236.
86. Lebon, G.; Edwards, P. C.; Leslie, A. G. W.; Tate, C. G. Molecular Determinants of CGS21680 Binding to the Human Adenosine A 2A Receptor S. Mol. Pharmacol. 2015, 87 (June), 907-915.
87. Rasmussen, S. G. F.; DeVree, B. T.; Zou, Y.; Kruse, A. C.; Chung, K. Y.; Kobilka, T. S.; Thian, F. S.; Chae, P. S.; Pardon, E.; Calinski, D.; et al. Crystal Structure of the β2 Adrenergic receptor-Gs Protein Complex. Nature 2011, 477 (7366), 549-555.
88. Scheerer, P.; Park, J. H.; Hildebrand, P. W.; Kim, Y. J.; Krauss, N.; Choe, H.-W.; Hofmann, K. P.; Ernst, O. P. Crystal Structure of Opsin in Its G-Protein-Interacting Conformation. Nature 2008, 455 (7212), 497-502.
89. Standfuss, J.; Edwards, P. C.; D'Antona, A.; Fransen, M.; Xie, G.; Oprian, D. D.; Schertler, G. F. X. The Structural Basis of Agonist-Induced Activation in Constitutively Active Rhodopsin. Nature 2011, 471 (7340), 656-660.
90. Cherezov, V.; Rosenbaum, D. M.; Hanson, M. a; Rasmussen, S. G. F.; Thian, F. S.; Kobilka, T. S.; Choi, H.-J.; Kuhn, P.; Weis, W. I.; Kobilka, B. K.; et al. High-Resolution Crystal Structure of an Engineered Human beta2-Adrenergic G Protein-Coupled Receptor. Science 2007, 318 (5854), 1258-1265.
91. Palczewski, K. Crystal Structure of Rhodopsin: A G Protein-Coupled Receptor. Science 2000, 289 (5480), 739-745.
92. Ballesteros, J. A.; Weinstein, H. Integrated Methods for the Construction of Three-Dimensional Models of Structure-function Relations in G Protein-Coupled Receptors. Methods Neurosci. 1995, 25, 366-428.
93. Ye, L.; Van Eps, N.; Zimmer, M.; Ernst, O. P.; Prosser, R. S. Activation of the A2A Adenosine G-Protein-Coupled Receptor by Conformational Selection. Nature 2016, 533 (7602), 265-268.
94. Kumar, V. Adenosine as an Endogenous Immunoregulator in Cancer Pathogenesis: Where to Go? Purinergic Signalling 2013, 9 (2), 145-165.
95. Morelli, M.; Carta, A. R.; Jenner, P. Adenosine Receptors in Health and Disease. Handb. Exp. Pharmacol. 2009, 193 (193), 589-615.
96. Gessi, S.; Varani, K.; Merighi, S.; Ongini, E.; Borea, P. A. A2A Adenosine Receptors in Human Peripheral Blood Cells. Br. J. Pharmacol. 2000, 129, 2-11.
97. Trevethick, M. a; Mantell, S. J.; Stuart, E. F.; Barnard, a; Wright, K. N.; Yeadon, M. Treating Lung Inflammation with Agonists of the Adenosine A2A Receptor: Promises, Problems and Potential Solutions. Br. J. Pharmacol. 2008, 155 (4), 463-474.
98. Hatfield, S.; Belikoff, B.; Lukashev, D.; Sitkovsky, M.; Ohta, A. The Antihypoxia-Adenosinergic Pathogenesis as a Result of Collateral Damage by Overactive Immune Cells. J. Leukocyte Biol. 2009, 86 (3), 545-548.
99. Ohta, A.; Sitkovsky, M. Role of G-Protein-Coupled Adenosine Receptors in Downregulation of Inflammation and Protection from Tissue Damage. Nature 2001, 414 (6866), 916-920.
100. Fozard, J. R.; Ellis, K. M.; Villela Dantas, M. F.; Tigani, B.; Mazzoni, L. Effects of CGS 21680, a Selective Adenosine A2A Receptor Agonist, on Allergic Airways Inflammation in the Rat. Eur. J. Pharmacol. 2002, 438 (3), 183-188.
101. Impellizzeri, D.; Di Paola, R.; Esposito, E.; Mazzon, E.; Paterniti, I.; Melani, A.; Bramanti, P.; Pedata, F.; Cuzzocrea, S. CGS 21680, an Agonist of the Adenosine (A 2A) Receptor, Decreases Acute Lung Inflammation. Eur. J. Pharmacol. 2011, 668 (1-2), 305-316.
102. Thiel, M.; Chouker, A.; Ohta, A.; Jackson, E.; Caldwell, C.; Smith, P.; Lukashev, D.; Bittmann, I.; Sitkovsky, M. V. Oxygenation Inhibits the Physiological Tissue-Protecting Mechanism and Thereby Exacerbates Acute Inflammatory Lung Injury. PLoS Biol. 2005, 3 (6), No. e174.
103. Mazar, J.; Rogachev, B.; Shaked, G.; Ziv, N. Y.; Czeiger, D.; Chaimovitz, C.; Zlotnik, M.; Mukmenev, I.; Byk, G.; Douvdevani, a. Involvement of Adenosine in the Antiinflammatory Action of Ketamine. Anesthesiology 2005, 102 (6), 1174-1181.
104. Svenningsson, P.; Le Moine, C.; Kull, B.; Sunahara, R.; Bloch, B.; Fredholm, B. B. Cellular Expression of Adenosine A(2a) Receptor Messenger RNA in the Rat CentralNervous System with Special Reference to Dopamine Innervated Areas. Neuroscience 1997, 80 (4), 1171-1185.
105. Mishina, M.; Ishiwata, K.; Kimura, Y.; Naganawa, M.; Oda, K.; Kobayashi, S.; Katayama, Y.; Ishii, K. Evaluation of Distribution of Adenosine A2A Receptors in Normal Human Brain Measured with [11C]TMSX PET. Synapse 2007, 61 (9), 778-784.
106. Pollack, A. E.; Fink, J. S. Adenosine Antagonists Potentiate D2 Dopamine-Dependent Activation of Fos in the Striatopallidal Pathway. Neuroscience 1995, 68 (3), 721-728.
107. Pintor, A.; Pèzzola, A.; Reggio, R.; Quarta, D.; Popoli, P. The mGlu5 Receptor Agonist CHPG Stimulates Striatal Glutamate Release: Possible Involvement of A2A Receptors. NeuroReport 2000, 11 (16), 3611-3614.
108. Tebano, M. T.; Martire, A.; Chiodi, V.; Pepponi, R.; Ferrante, A.; Domenici, M. R.; Frank, C.; Chen, J. F.; Ledent, C.; Popoli, P. Adenosine A2A Receptors Enable the Synaptic Effects of Cannabinoid CB1 Receptors in the Rodent Striatum. J. Neurochem. 2009, 110 (6), 1921-1930.
109. Uchida, S.-I.; Tashiro, T.; Kawai-Uchida, M.; Mori, A.; Jenner, P.; Kanda, T. The Adenosine A2A-Receptor Antagonist Istradefylline Enhances the Motor Response of L-DOPA Without Worsening Dyskinesia in MPTP-Treated Common Marmosets. J. Pharmacol. Sci. 2014, 124 (4), 480-485.
110. Dungo, R.; Deeks, E. D. Istradefylline: First Global Approval. Drugs 2013, 73 (8), 875-882.
111. Hauser, R. A.; Stocchi, F.; Rascol, O.; Huyck, S. B.; Capece, R.; Ho, T. W.; Sklar, P.; Lines, C.; Michelson, D.; Hewitt, D. Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease: Two Randomized Clinical Trials and Lessons Learned. JAMA Neurol. 2015, 72 (12), 1491-1500.
112. Piersanti, G.; Bartoccini, F.; Lucarini, S.; Cabri, W.; Stasi, M. A.; Riccioni, T.; Borsini, F.; Tarzia, G.; Minetti, P. Synthesis and Biological Evaluation of Metabolites of 2-N-Butyl-9-Methyl-8-[1, 2, 3]triazol-2-Yl-9H-Purin-6-Ylamine (ST1535), a Potent Antagonist of the A2A Adenosine Receptor for the Treatment of Parkinson's Disease. J. Med. Chem. 2013, 56 (13), 5456-5463.
113. Hauser, R. A.; Olanow, C. W.; Kieburtz, K. D.; Pourcher, E.; Docu-Axelerad, A.; Lew, M.; Kozyolkin, O.; Neale, A.; Resburg, C.; Meya, U.; et al. Tozadenant (SYN115) in Patients with Parkinson's Disease Who Have Motor Fluctuations on Levodopa: A Phase 2b, Double-Blind, Randomised Trial. Lancet Neurol. 2014, 13 (8), 767-776.
114. Kreamer, K. M. Immune Checkpoint Blockade: A New Paradigm in Treating Advanced Cancer. J. Adv. Pract. Oncol. 2014, 5 (6), 418-431.
115. Blay, J.; White, T. D.; Hoskin, D. W. The Extracellular Fluid of Solid Carcinomas Contains Immunosuppressive Concentrations of Adenosine. Cancer Res. 1997, 57 (902), 2602-2605.
116. Beavis, P. A.; Divisekera, U.; Paget, C.; Chow, M. T.; John, L. B.; Devaud, C.; Dwyer, K.; Stagg, J.; Smyth, M. J.; Darcy, P. K. Blockade of A2A Receptors Potently Suppresses the Metastasis of CD73+ Tumors. Proc. Natl. Acad. Sci. U. S. A. 2013, 110 (36), 14711-14716.
117. Waickman, A. T.; Alme, A.; Senaldi, L.; Zarek, P. E.; Horton, M.; Powell, J. D. Enhancement of Tumor Immunotherapy by Deletion of the A2A Adenosine Receptor. Cancer Immunol. Immunother. 2012, 61 (6), 917-926.
118. Beavis, P. A.; Milenkovski, N.; Henderson, M. A.; John, L. B.; Allard, B.; Loi, S.; Kershaw, M. H.; Stagg, J.; Darcy, P. K. Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-Cell Responses. Cancer Immunol. Res. 2015, 3, 506-517.
119. Iannone, R.; Miele, L.; Maiolino, P.; Pinto, A.; Morello, S. Adenosine Limits the Therapeutic Effectiveness of Anti-CTLA4 mAb in a Mouse Melanoma Model. Am. J. Cancer Res. 2014, 4 (2), 172-181.
120. Langmead, C. J.; Andrews, S. P.; Congreve, M.; Errey, J. C.; Hurrell, E.; Marshall, F. H.; Mason, J. S.; Richardson, C. M.; Robertson, N.; Zhukov, A.; et al. Identification of Novel Adenosine A(2A) Receptor Antagonists by Virtual Screening. J. Med. Chem. 2012, 55 (5), 1904-1909.
121. Gillespie, R. J.; Bamford, S. J.; Botting, R.; Comer, M.; Denny, S.; Gaur, S.; Griffin, M.; Jordan, A. M.; Knight, A. R.; Lerpiniere, J.; et al. Antagonists of the Human A2A Adenosine Receptor. 4. Design, Synthesis, and Preclinical Evaluation of 7-Aryltriazolo[4, 5-D]-pyrimidines. J. Med. Chem. 2009, 52 (1), 33-47.
122. Kooistra, A. J.; Roumen, L.; Leurs, R.; de Esch, I. J. P.; de Graaf, C. From Heptahelical Bundle to Hits from the Haystack: Structure-Based Virtual Screening for GPCR Ligands. In G Protein Coupled Receptors: Modeling, Activation, Interactions and Virtual Screening; Conn, P. M., Ed.; Methods in Enzymology, Vol. 522; Elsevier: 2013; Chapt. 15, pp 279-336; DOI: 10.1016/B978-0-12-407865-9.00015-7.
123. Piirainen, H.; Ashok, Y.; Nanekar, R. T.; Jaakola, V. P. Structural Features of Adenosine Receptors: From Crystal to Function. Biochim. Biophys. Acta, Biomembr. 2011, 1808 (5), 1233-1244.
124. Andrews, S. P.; Brown, G. a.; Christopher, J. a. Structure-Based and Fragment-Based GPCR Drug Discovery. ChemMedChem 2014, 9 (2), 256-275.
125. Rataj, K.; Witek, J.; Mordalski, S.; Kosciolek, T.; Bojarski, A. J. Impact of Template Choice on Homology Model Efficiency in Virtual Screening. J. Chem. Inf. Model. 2014, 54 (6), 1661-1668.
126. Cherezov, V.; Rosenbaum, D. M.; Hanson, M. A.; Rasmussen, S. G.; Thian, F. S.; Kobilka, T. S.; Choi, H. J.; Kuhn, P.; Weis, W. I.; Kobilka, B. K.; Stevens, R. C. High-Resolution Crystal Structure of an Engineered Human beta2-Adrenergic G Protein-Coupled Receptor. Science 2007, 318 (5854), 1258-1265.
127. Wei, J.; Qu, W.; Ye, Y.; Gao, Q. 3D Pharmacophore Based Virtual Screening of A(2A) Adenosine Receptor Antagonists. Protein Pept. Lett. 2010, 17 (3), 332-339.
128. Katritch, V.; Kufareva, I.; Abagyan, R. Structure Based Prediction of Subtype-Selectivity for Adenosine Receptor Antagonists. Neuropharmacology 2011, 60 (1), 108-115.
129. Sirci, F.; Goracci, L.; Rodriguez, D.; van Muijlwijk-Koezen, J.; Gutierrez-de-Teran, H.; Mannhold, R. Ligand-, Structure-And Pharmacophore-Based Molecular Fingerprints: A Case Study on Adenosine A(1), A(2A), A(2B), and A(3) Receptor Antagonists. J. Comput.-Aided Mol. Des. 2012, 26 (11), 1247-1266.
130. Michino, M.; Abola, E.; Brooks, C. L., III; Dixon, J. S.; Moult, J.; Stevens, R. C. Community-Wide Assessment of GPCR Structure Modelling and Ligand Docking: GPCR Dock 2008. Nat. Rev. Drug Discovery 2009, 8, 455-463.
131. Katritch, V.; Rueda, M.; Lam, P. C.; Yeager, M.; Abagyan, R. GPCR 3D Homology Models for Ligand Screening: Lessons Learned from Blind Predictions of Adenosine A2a Receptor Complex. Proteins: Struct., Funct., Genet. 2010, 78 (1), 197-211.
132. Katritch, V.; Jaakola, V. P.; Lane, J. R.; Lin, J.; Ijzerman, A. P.; Yeager, M.; Kufareva, I.; Stevens, R. C.; Abagyan, R. Structure-Based Discovery of Novel Chemotypes for Adenosine A(2A) Receptor Antagonists. J. Med. Chem. 2010, 53 (4), 1799-1809.
133. Lenselink, E. B.; Beuming, T.; Sherman, W.; Van Vlijmen, H. W. T.; Ijzerman, A. P. Selecting an Optimal Number of Binding Site Waters to Improve Virtual Screening Enrichments against the Adenosine A2A Receptor. J. Chem. Inf. Model. 2014, 54 (6), 1737-1746.
134. Carlsson, J.; Yoo, L.; Gao, Z. G.; Irwin, J. J.; Shoichet, B. K.; Jacobson, K. A. Structure-Based Discovery of A2A Adenosine Receptor Ligands. J. Med. Chem. 2010, 53 (9), 3748-3755.
135. Areias, F.; Costa, M.; Castro, M.; Brea, J.; Gregori-Puigjane, E.; Proenca, M. F.; Mestres, J.; Loza, M. I. New Chromene Scaffolds for Adenosine A(2A) Receptors: Synthesis, Pharmacology and Structure-Activity Relationships. Eur. J. Med. Chem. 2012, 54, 303-310.
136. van der Horst, E.; van der Pijl, R.; Mulder-Krieger, T.; Bender, A.; Ijzerman, A. P. Substructure-Based Virtual Screening for Adenosine A2A Receptor Ligands. ChemMedChem 2011, 6 (12), 2302-2311.
137. Sanders, M. P. A.; Roumen, L.; van der Horst, E.; Lane, J. R.; Vischer, H. F.; van Offenbeek, J.; de Vries, H.; Verhoeven, S.; Chow, K. Y.; Verkaar, F.; et al. A Prospective Cross-Screening Study on G-Protein-Coupled Receptors: Lessons Learned in Virtual Compound Library Design. J. Med. Chem. 2012, 55, 5311-5325.
138. van Westen, G. J. P.; van den Hoven, O. O.; van der Pijl, R.; Mulder-Krieger, T.; de Vries, H.; Wegner, J. K.; Ijzerman, A. P.; van Vlijmen, H. W. T.; Bender, A. Identifying Novel Adenosine Receptor Ligands by Simultaneous Proteochemometric Modeling of Rat and Human Bioactivity Data. J. Med. Chem. 2012, 55 (16), 7010-7020.
139. Deflorian, F.; Kumar, T. S.; Phan, K.; Gao, Z.-G.; Xu, F.; Wu, H.; Katritch, V.; Stevens, R. C.; Jacobson, K. A. Evaluation of Molecular Modeling of Agonist Binding in Light of the Crystallographic Structure of an Agonist-Bound A(2)A Adenosine Receptor. J. Med. Chem. 2012, 55 (1), 538-552.
140. Kera Nen, H.; Aqvist, J.; Gutiérrez-De-Terán, H. Free Energy Calculations of A 2A Adenosine Receptor Mutation Effects on Agonist Binding. Chem. Commun. 2015, 51 (17), 3522-3525.
141. Tosh, D. K.; Phan, K.; Gao, Z. G.; Gakh, A. A.; Xu, F.; Deflorian, F.; Abagyan, R.; Stevens, R. C.; Jacobson, K. A.; Katritch, V. Optimization of Adenosine 5′-carboxamide Derivatives as Adenosine Receptor Agonists Using Structure-Based Ligand Design and Fragment Screening. J. Med. Chem. 2012, 55 (9), 4297-4308.
142. Sabbadin, D.; Ciancetta, A.; Moro, S. Bridging Molecular Docking to Membrane Molecular Dynamics to Investigate GPCRLigand Recognition: The Human A2A Adenosine Receptor as a Key Study. J. Chem. Inf. Model. 2014, 54 (1), 169-183.
143. Sabbadin, D.; Ciancetta, A.; Deganutti, G.; Cuzzolin, A.; Moro, S. Exploring the Recognition Pathway at theHuman A2A Adenosine Receptor of the Endogenous Agonist Adenosine Using Supervised Molecular Dynamics Simulations. MedChemComm 2015, 6 (6), 1081-1085.
144. Bortolato, A.; Tehan, B. G.; Bodnarchuk, M. S.; Essex, J. W.; Mason, J. S. Water Network Perturbation in Ligand Binding: Adenosine A2A Antagonists as a Case Study. J. Chem. Inf. Model. 2013, 53 (7), 1700-1713.
145. Higgs, C.; Beuming, T.; Sherman, W. Hydration Site Thermodynamics Explain SARs for Triazolylpurines Analogues Binding to the A2A Receptor. ACS Med. Chem. Lett. 2010, 1 (4), 160-164.
146. Mason, J. S.; Bortolato, A.; Weiss, D. R.; Deflorian, F.; Tehan, B.; Marshall, F. H. High End GPCR Design: Crafted Ligand Design and Druggability Analysis Using Protein Structure, Lipophilic Hotspots and Explicit Water Networks. Silico Pharmacol. 2013, 1 (1), 23.
147. Jörg, M.; Shonberg, J.; Mak, F. S.; Miller, N. D.; Yuriev, E.; Scammells, P. J.; Capuano, B. Novel Adenosine A2A Receptor Ligands: A Synthetic, Functional and Computational Investigation of Selected Literature Adenosine A2A Receptor Antagonists for Extending into Extracellular Space. Bioorg. Med. Chem. Lett. 2013, 23 (11), 3427-3433.
148. Andrews, S. P.; Mason, J. S.; Hurrell, E.; Congreve, M. Structure-Based Drug Design of Chromone Antagonists of the Adenosine A2A Receptor. MedChemComm 2014, 5 (5), 571-575.
149. Mason, J. S.; Bortolato, A.; Congreve, M.; Marshall, F. H. New Insights from Structural Biology into the Druggability of G Protein-Coupled Receptors. Trends Pharmacol. Sci. 2012, 33 (5), 249-260.
150. Carlsson, J.; Tosh, D. K.; Phan, K.; Gao, Z.-G.; Jacobson, K. A. Structure-Activity Relationships and Molecular Modeling of 1, 2, 4-Triazoles as Adenosine Receptor Antagonists. ACS Med. Chem. Lett. 2012, 3 (9), 715-720.
151. Zhukov, A.; Andrews, S. P.; Errey, J. C.; Robertson, N.; Tehan, B.; Mason, J. S.; Marshall, F. H.; Weir, M.; Congreve, M. Biophysical Mapping of the Adenosine A2A Receptor. J. Med. Chem. 2011, 54 (13), 4312-4323.
152. Segala, E.; Errey, J. C.; Fiez-Vandal, C.; Zhukov, A.; Cooke, R. M. Biosensor-Based Affinities and Binding Kinetics of Small Molecule Antagonists to the Adenosine A2A Receptor Reconstituted in HDL like Particles. FEBS Lett. 2015, 589 (13), 1399-1405.
153. Andrews, S. P.; Tehan, B. Stabilised G Protein-Coupled Receptors in Structure-Based Drug Design: A Case Study with Adenosine A2A Receptor. MedChemComm 2013, 4, 52-67.